Chief Operating Officer Christopher Boerner will take up the role from Nov. 1.
Outgoing CEO Giovanni will continue as executive chairman of the company's board. The company also appointed Adam Lenkowsky as chief commercial officer.
Caforio's biggest move as chief executive was the company's $74 billion buyout of Celgene in 2019, which boosted the company's revenue as sales of its top-selling cancer drug Opdivo slowed due to stiff competition from Merck's Keytruda.Bristol Myers shares rose 0.39% to $68.29 in after-hours trading.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Bristol-Myers CEO Giovanni Caforio to Leave DrugmakerChief Commercialization Officer Christopher Boerner to take over after Giovanni Caforio retires, the company said.
続きを読む »
Leading edge AI company moves from San Francisco to Allen - CEO SpotlightMelissa Solis, CEO of Ibenta, joins David Johnson on today's CEO Spotlight.
続きを読む »
Pioneer Natural CEO Scott Sheffield to retire, COO Dealy to become shale company’s next CEOShares of Pioneer Natural Resources Co. fell more than 2% in the extended session Wednesday after the exploration and production company said that its board...
続きを読む »
Sundar Pichai got paid 808 times the median Google worker payGoogle CEO Sundar Pichai's 2022 pay details are out: $2 million in base salary, $6 million for private security and his once-every-three-years treat — an absolutely massive stock award.
続きを読む »
WWD Beauty CEO Summit
続きを読む »